Evaluation of the in vitro antitumor effect of the association between doxorubicin and crotamine toxinAssessment of the in vitro antitumor effect of the association between doxorubicin and crotamine toxin

as a form of dynamic monitoring, in real time from start to finish, of phenotypic events of B16F10 tumor cells treated with DOX (0.2 nM) and in association with Cta toxin (200 nM) for more than 72h. Results: The toxin used alone at the minimum concentration of 200 nM exerted 40% toxicity and at higher concentrations (1000 and 5000 nM) decreased cell viability more significantly. Dox, in turn, at concentrations (0.02 – 0.1 nM) showed toxicity between 20 and 80%. On the other hand, and surprisingly, the pharmacological association between Cta (200 nM) and Dox (0.2 nM) was able to exert cytotoxicity around 60%. Conclusion: The combination of the nanocarrier toxin Cta with the chemotherapeutic Doxorubicin in minimal concentrations was able to improve the antiproliferative activity (potentiating effect) observed in B16F10 cells, thus contributing to new studies involving alternative/complementary therapies for the control of cell replication in different tumor lineages and /or in vivo models.